- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02614937
Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion
Open Label Squalamine Lactate Ophthalmic Solution for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
At baseline, all eyes underwent ETDRS visual acuity measurements at 4 meters, a complete ophthalmological evaluation, SD-OCT imaging of the macula, and fluorescein angiographic assessment of capillary perfusion in the macula and peripheral fundus. All eyes received an initial 10 week mandatory loading period of topical squalamine therapy.
All eyes received mandatory intravitreal injections of ranibizumab 0.5mg at the conclusions of weeks 2 and 6. At the conclusion of week 10, eyes were randomized in a 1:1 ratio to continue squalamine drops bid or discontinue squalamine drops in the study eye. All eyes were examined every 4 weeks through the week 38 endpoint and were eligible to receive additional as needed ranibizumab 0.5mg injections starting at the conclusion of week 10 and every 4 weeks thereafter through week 34 depending upon prespecified visual acuity and OCT retreatment criteria.
Any eye with a decrease of 5 or more ETDRS letters or increase in CST on OCT of 50uM or more from their best previous measurements automatically received an additional ranibizumab 0.5mg injection beginning at the conclusion of week 10.
Eyes randomized to continue squalamine drops did so through the week 38 endpoint. SD-OCT measurements of the macula were obtained at every study visit. Fluorescein angiograms were performed on the study eye at baseline, weeks 10 and 38.
Safety endpoints included all adverse events spontaneously reported, elicited or observed were documented by the investigators at any visit.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Eyes with treatment naïve, center involving macular edema secondary to BRVO, HRVO or CRVO in patients of at least 40 years of age
- Macular edema of 1-4 months duration prior to the baseline visit
- Best corrected baseline ETDRS visual acuity of 20/40 to 20/320 Snellen equivalent using the 4 meter testing method
- Baseline CST greater than or equal to 325uM using SD-OCT imaging
- Less than 50% foveal capillary ring disruption as defined by fluorescein angiography (FA)
- Absence of dense intraretinal or subretinal hemorrhage and or lipid through the foveal center
- Absence of subfoveal fibrosis or hyperpigmentation.
Exclusion Criteria:
- Eyes with ocular pathology other than RVO related macular edema such as clinically significant cataract or media opacity, diabetic retinopathy, macular degeneration, glaucoma, uveitis, epiretinal membrane, vitreomacular traction or intraocular tumor
- Intraocular surgery within 6 months prior to baseline
- Two-plus or greater afferent pupillary defect (APD) in the study eye
- Likelihood of evidence driven indication for peripheral scatter photocoagulation within 6 months of recruitment
- History of previous intravitreal pharmacologic treatment of any kind in the study eye
- History of previous retinal laser photocoagulation of any kind in the study eye
- History of intravitreal anti-VEGF therapy in the fellow eye within 6 months prior to baseline
- Any evidence of baseline ocular neovascularization such as disc neovascularization, preretinal neovascularization, iris or angle neovascularization in the study eye
- Eyes that have shown spontaneous improvement within the preceding 3 months defined as an improvement of best corrected visual acuity of greater than 15 ETDRS letters or thinning of the CST on OCT of greater than 20%
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Squalamine and ranibizumab to Week 10
All eyes received an initial 10 week mandatory loading period of topical Squalamine Lactate Ophthalmic Solution, 0.2% therapy. All eyes received mandatory intravitreal injections of ranibizumab 0.5mg at the conclusions of weeks 2 and 6. Randomize at Week 10 to 2 different groups - Squalamine and No Squalamine, continue PRN ranibizumab in both groups |
0.5 mg IVT ranibizumab
Other Names:
Squalamine Lactate Ophthalmic Solution BID
|
Experimental: Continue Squalamine, ranibizumab PRN
Continue use of Squalamine Lactate Ophthalmic Solution, 0.2% after Week 10; continue ranibizumab 0.5 mg IVT PRN
|
0.5 mg IVT ranibizumab
Other Names:
|
Experimental: Stop Squalamine, ranibizumab PRN
Discontinue use of Squalamine Lactate Ophthalmic Solution, 0.2% after Week 10; continue ranibizumab 0.5 mg IVT PRN
|
0.5 mg IVT ranibizumab
Other Names:
Squalamine Lactate Ophthalmic Solution BID
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual Function - Efficacy
Time Frame: Baseline to Week 38
|
Mean change in ETDRS letter score from baseline
|
Baseline to Week 38
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual Function - Efficacy
Time Frame: Baseline to Week 38
|
Eyes with visual outcomes of 20/40 or better at Week 38 compared to Baseline Visit
|
Baseline to Week 38
|
Retinal Anatomy - Efficacy
Time Frame: Baseline to Week 38
|
Proportion of eyes with Central Subfield Thickness (CST) on SD-OCT less than 325 microns at Week 38
|
Baseline to Week 38
|
Safety and Tolerability as measured by adverse event reporting and ophthalmologic examination from Baseline to Week 38
Time Frame: Baseline to Week 38
|
Safety as measured by adverse event reporting and ophthalmologic examination from Baseline to Week 38
|
Baseline to Week 38
|
Concomitant ranibizumab administration - efficacy
Time Frame: Baseline to Week 38
|
Number of injections of 0.5 mg ranibizumab to keep edema resolved from Week 2 through Week 34 of study
|
Baseline to Week 38
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: John Wroblewski, MD, Cumberland Valley Retinal Consultants, Hagerstown, MD
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Eye Diseases
- Retinal Degeneration
- Retinal Diseases
- Embolism and Thrombosis
- Venous Thrombosis
- Thrombosis
- Macular Degeneration
- Macular Edema
- Retinal Vein Occlusion
- Edema
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antineoplastic Agents
- Protective Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Anti-Bacterial Agents
- Pharmaceutical Solutions
- Anticarcinogenic Agents
- Ranibizumab
- Ophthalmic Solutions
- Squalamine
Other Study ID Numbers
- OHR-004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Macular Edema
-
Federico II UniversityCompletedPseudophakic Cystoid Macular Edema
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
Postgraduate Institute of Medical Education and...CompletedDiabetic Macular Edema | Vision Disorders | Macular Edema, Cystoid | Clinically Significant Macular EdemaIndia
-
OcugenNot yet recruitingDiabetic Macular Edema | Center Involved Diabetic Macular Edema
-
OculisICON plcRecruitingDiabetic Macular EdemaUnited States
-
Novartis PharmaceuticalsNot yet recruiting
-
Hoffmann-La RocheRecruitingUveitic Macular EdemaKorea, Republic of, United Kingdom, China, United States, Netherlands, Canada, Israel, Austria, Brazil, Italy, Taiwan, Poland, Portugal, Mexico
-
Vista KlinikNot yet recruitingDiabetic Macular Edema
-
Chinese University of Hong KongRecruiting
-
Laboratorios Sophia S.A de C.V.RecruitingDiabetic Macular EdemaColombia, Mexico
Clinical Trials on ranibizumab
-
University of Campania "Luigi Vanvitelli"Completed
-
Hanscom, Thomas, M.D.Genentech, Inc.CompletedCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionUnited States
-
University of Illinois at ChicagoGenentech, Inc.WithdrawnGlaucoma | Neovascular Glaucoma | New Onset Glaucoma | New Onset Neovascular Glaucoma
-
Especialistas en Retina Medica y Quirurgica Grupo...Centro de Retina Medica y Quirurgica S.C.CompletedDiabetic Macular EdemaArgentina, Mexico
-
Lupin Ltd.RecruitingNeovascular Age-related Macular DegenerationIndia
-
Hawaii Pacific HealthGenentech, Inc.CompletedPolypoidal Choroidal Vasculopathy | PCVUnited States
-
New England Retina AssociatesGenentech, Inc.CompletedChoroidal MelanomaUnited States
-
Samsung Bioepis Co., Ltd.CompletedAge-Related Macular DegenerationKorea, Republic of, United States, India, Germany, Hungary, United Kingdom, Czechia, Poland, Russian Federation
-
Peter A Campochiaro, MDGenentech, Inc.CompletedRetinal Vein OcclusionUnited States
-
Instituto de Olhos de GoianiaCompleted